Compare Palo Alto Networks Inc (PANW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Palo Alto Networks Inc trades at $403.96 (market cap $331.76B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Palo Alto Networks Inc is far larger — about 4.4× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PANW | REGN | |
|---|---|---|
Market Cap | $331.76B | $76.14B |
Volume | 3,886,927 | 500,239 |
Sector | Technology | Health |
52-Week High | $419.91 | $852.03 |
52-Week Low | $141.67 | $557.73 |
Typical Hold Time | 82 Days | 107 Days |
Enterprise Value | $331.19B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but maintains a bullish technical outlook with strong moving average signals. The company demonstrates robust revenue growth, reaching $9.22B in 2025, though net margins compressed to 2.67%. Recent AI security initiatives, including Unit 42 AI defense service, position PANW for continued growth in the cybersecurity sector.
PANW presents a mixed investment case with strong AI-driven growth potential offset by premium valuations (P/E 1,013.93, P/S 26.99). Analyst consensus remains strongly bullish (72% buy ratings) with a $398.70 price target. Key risks include valuation sensitivity and competitive pressures in the rapidly evolving cybersecurity landscape.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
